REV-MED recently signed a Memorandum of Understanding (MOU) with Seoul Bio Clinic to advance research in regenerative medicine using autologous stem cells.
Under this agreement, the two institutions will collaborate on clinical studies, research on new indications, and academic publications while also developing innovative business models. Specifically, the partnership focuses on:
- Expanding applications for autologous stem cell therapy
- Co-developing related medical devices
- Investing in advanced research and technology
Dr. Sang-Keun Jang, a neurosurgeon and head of Seoul Bio Clinic, brings over 20 years of experience in treating conditions such as stroke, cerebral infarction, spinal cord injuries, dementia, Parkinson's disease, and diabetes using adult stem cells. His extensive clinical expertise aligns with the goals of this partnership to enhance the potential of stem cell therapies.
Founded in 2009, REV-MED specializes in bio-kits capable of concentrating and extracting growth and regenerative factors from blood, bone marrow, and adipose tissue. The company continues to innovate in the development and commercialization of autologous blood concentration systems for stem cell therapy.
CEO Bongkeun Shin stated, “Through this agreement, we aim to invest actively in R&D to enable autologous stem cells to benefit more medical fields.”
Source: HealthTrends (http://www.k-health.com)
REV-MED recently signed a Memorandum of Understanding (MOU) with Seoul Bio Clinic to advance research in regenerative medicine using autologous stem cells.
Under this agreement, the two institutions will collaborate on clinical studies, research on new indications, and academic publications while also developing innovative business models. Specifically, the partnership focuses on:
Dr. Sang-Keun Jang, a neurosurgeon and head of Seoul Bio Clinic, brings over 20 years of experience in treating conditions such as stroke, cerebral infarction, spinal cord injuries, dementia, Parkinson's disease, and diabetes using adult stem cells. His extensive clinical expertise aligns with the goals of this partnership to enhance the potential of stem cell therapies.
Founded in 2009, REV-MED specializes in bio-kits capable of concentrating and extracting growth and regenerative factors from blood, bone marrow, and adipose tissue. The company continues to innovate in the development and commercialization of autologous blood concentration systems for stem cell therapy.
CEO Bongkeun Shin stated, “Through this agreement, we aim to invest actively in R&D to enable autologous stem cells to benefit more medical fields.”
Source: HealthTrends (http://www.k-health.com)